Skip to main content
BMRN logo

BMRN · Biomarin Pharmaceutical Inc

Track BMRN — free
$61.42 -0.01 (-0.02%)
Market Cap
$11.90B
Shares
193.69M
Volume · Nov 19 5.2M Avg daily vol (3M) 2.26M

Price & Indicators

Close$61.42 Open$61.14 Day$61.00–64.00 52W close$49.67–70.24 Avg vol 30d2.6M Short int14.1M · 7.3% of shares · 5.8d Short vol56% Last earningsNov 2, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Feb 22, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 17
Investor event
Peak Revenue Views: $1.4 Billion Gallifold, $1.2 Billion OpFolda

BioMarin said the Amicus acquisition closed in April, with Q3 the first quarter of combined results. It sees peak revenue of $1.4 billion for Gallifold and $1.2 billion for OpFolda. The company also noted pending FDA approval for Voxogo in hypochondroplasia.

3 source passages
The transaction closed in April, so Q3 was just our first quarter of the combined company results Our views of peak revenue for Gallifold and Pombility and OpFolda are $1.4 billion and $1.2 billion, respectively. we have the pending FDA approval of Voxogo in hypochondroplasia. Open the document at this passage
Nov 16
Investor event
Revenue up 60% with pipeline catalysts ahead

Biomarin said revenue rose 60% since 2023, supported by rare-disease commercialization and a pipeline approaching major clinical catalysts.

3 source passages
since 2023, we've increased revenue by 60% we're now at the stage in 27 where we start to see a bunch of really exciting clinical catalysts we've dramatically improved the financial performance of the company Open the document at this passage
Nov 11
Investor event
Total revenue reaches $1 billion as pipeline expands

Biomarin reported Q3 revenue growth of 32% and first-ever $1 billion total revenue while adding four pipeline assets. Management expects roughly $220 million of operating-expense synergies to be fully realized in 2028.

5 source passages
Very strong Q3 with revenue growth of 32%. We reached $1 billion of total revenue for the first time in the company history. We’ve added four new assets to our pipeline this year. We think that synergies of roughly $220 million will be fully realized for a full year in 2028. Which then gets to a healthy inflection on what was already the growing profitability profile of historical Biomarin. Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue growth contrasts with wider quarterly losses

Biomarin Pharmaceutical Inc reported nine-month 2026 total revenues of 2,780.6 million versus 2,346.7 million in 2025, while third-quarter net loss widened to (122.8) million from (30.7) million.

Revenue $1.02B ▲ 32.0% Net loss $122.83M Diluted EPS -$0.63
Read from the MD&A section
3 source passages
Three Months EndedSeptember 30, | | Nine Months EndedSeptember 30, | | 2026 | 2025 Total revenues | 1,024.6 | 776.1 | 2,780.6 | 2,346.7 Net income (loss) | (122.8) | (30.7) | 27.5 | 395.5 Open the document at this passage
Nov 2
Earnings call
Revenue tops $1 billion; guidance set at $3.8 billion-$3.9 billion

Biomarin surpassed $1 billion in quarterly revenue for the first time, growing 32% year over year, but reduced full-year 2026 guidance to between $3.8 billion and $3.9 billion due to order timing and Middle East disruption.

6 source passages
Biomarin Pharmaceutical, Inc. strong demand across our diversified portfolio of innovative therapies drove 32% year-over-year growth in the third quarter, surpassing $1 billion in quarterly revenues for the first time in our history. As Alexander and Kristen have already covered the key revenue details for Q3, I will cover the financial impact of our two recent business development transactions, some revenue timing and geopolitical dynamics that we are observing, and the expected associated earnings per share impacts in 2026. we are updating our full-year total revenue guidance range to between $3.8 billion and $3.9 billion. The driver of the change is order timing and not underlying patient demand. A second factor is the prolonged conflict in the Middle East. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$3.66B
Trailing 12 months
Net income (TTM)
−$19.11M
Trailing 12 months
Revenue growth YoY
+32.0%
Year over year
Operating margin
3.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
4.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$3.44B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.8%
Year over year · more shares
Price change (1Y)
+13.4%
Trailing year
Short interest
7.3%
Latest settlement · 5.8 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26

TL;DR. BioMarin reported Q2 2026 revenue up 20% year-over-year to $990 million and raised full-year 2026 guidance for total revenues, Voxzogo, and non-GAAP diluted EPS, driven by strong demand and initial contributions from the recently closed Amicus acquisition (Galafold and Pombiliti+Opfolda), while integration-related costs and higher interest expense pressured GAAP and non-GAAP earnings.

Bullish
  • + Q2 total revenue grew 20% Y/Y to $990 million with raised full-year 2026 guidance
  • + Raised full-year 2026 Voxzogo revenue guidance to at least $1 billion on 14% Q2 Voxzogo growth
  • + Galafold and Pombiliti+Opfolda peak revenue potential of $2.6 billion with ~$220M synergies fully realized in 2028
  • + Submitted Voxzogo sNDA for hypochondroplasia with potential 2027 launch
  • + Deleverage target pulled forward ~1 year to below 2.5x gross leverage by mid-2027
Bearish
  • − GAAP net income fell 81% Y/Y to $45M due to Amicus acquisition costs and higher interest expense
  • − ~$200M annualized acquisition-related interest expense expected to weigh on near-term earnings
  • − Discontinued BMN 401 development after failing an ENPP1 deficiency co-primary endpoint

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Very Strong Sentiment Very Bearish Fundamentals Strong Quant / Vol Moderate
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Neutral
50 / 200-day cross Death cross
Price vs 200-day avg +5%
above
Price vs 50-day avg +5%
above
RSI (14) 64
neutral
MACD trend Positive
52-week position 57%
mid-range
Volume (OBV) Bearish div.
distributing
Momentum
relative strength
Very Strong
1-month return +8%
trailing
6-month return +12%
trailing
YTD return +3%
this year
Relative strength +17%
vs S&P · 6-mo
Sentiment
smart money
Very Bearish
Trend (MA cross) Death cross
50d $58 › 200d $59 — 200d above 50d
Institutional flow Distributing
-0% holders QoQ · +77 funds added
Insider flow Distributing
Net -$1.5M over 90 days · 100% sells
Short interest Rising
7.29% of shares out · ▲ +17.2% MoM · 5.8 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
570 holders — mid 3-yr range
Squeeze score 89
high risk · 0–100
Fundamentals
Strong
Revenue growth +18%
Y/Y
EPS growth −19%
Y/Y
Free cash flow $725.0M
Balance sheet $714.5M
net cash
Quant / Vol
risk profile
Moderate
Volatility 36%
annualized · 1-yr
Max drawdown −23%
past year
ATR 3.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 2 of last 2
Latest guidance · from the 8-K filed Nov 2, 2026
2028
GAAP cost synergies $280M
Cost synergies $220M
2026 Full-Year
Non-GAAP Diluted EPS Lowered $2.80 – $3.10
Feb 23, 2026 $4.95 – $5.15 changed to Nov 2, 2026 $2.80 – $3.10
Previous outlook earlier release · from the 8-K filed Oct 6, 2026

Still-open targets the latest release did not restate under the same label.

Total pre-tax charges (acquired IPR&D charges and ongoing operat · full year 2026 $320M
Guided vs delivered · last 2 settled
GAAP Diluted EPS Full-year 2023
guided $0.85 – $1.05
$0.87 In line
Full-year 2020 revenues full year 2020
guided $1.85B – $1.95B
$1.86B In line

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Neutral
2 · 2 · 3
50 / 200-day cross
Death cross Bearish
Price vs 200-day avg
+5% Bullish
Price vs 50-day avg
+5% Bullish
RSI (14)
64 Neutral
MACD trend
Positive Bullish
52-week position
57% Neutral
Volume (OBV)
Bearish div. Bearish
Market signals — smart money & positioning
Bearish · 4 of 6
Trend (MA cross) Death cross
50d $58 › 200d $59 — 200d above 50d
Institutional flow Distributing
-0% holders QoQ · +77 funds added
Insider flow Distributing
Net -$1.5M over 90 days · 100% sells
Short interest Rising
7.29% of shares out · ▲ +17.2% MoM · 5.8 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Steady
570 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $50 Now $61 · 57% Range high $70
vs 200-day avg +5% vs 50-day avg +5% 50-day below 200-day death cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
children with achondroplasia in 58 countries around the world 58 as of the end of the third quarter of 2026 —
Non-GAAP Income non-GAAP $430M nine months ended September 30, 2026 —
number of children treated with VOXZOGO globally 17% third quarter of 2026 —
number of patients treated with GALAFOLD 13% third quarter of 2026 —
number of patients treated with POMBILITI + OPFOLDA 69% third quarter of 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BMRN
Biomarin Pharmaceutical Inc
this stock
$11.90B +3.3% +17.6% — 7.3%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
570
% held
95.8%
Net QoQ
-8.5M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
529
View
Short & Settlement
Short Interest Rising
Shares short
14.1M
Days to cover
5.8d
Change
+2.1M sh
View
Short Volume
Short vol %
56%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
19.2K
Value
$1.1M
As of
Oct 27, 2026
View
Off-Exchange
Off-exchange %
38.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$1.5M
Buyers / Sellers
0 / 2
Buyers Sellers
View
Congressional Trades Sell
Member
Daniel Goldman
Amount
$1.0K–$15.0K
Traded
Mar 6, 2023
View
Financials
Financials
Revenue (FY)
$3.2B
Net income (FY)
$348.9M
EPS diluted
$1.80
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 17, 2026
This year
34

BioMarin said the Amicus acquisition closed in April, with Q3 the first quarter of combined results. It sees peak revenue of $1.4 billion for Gallifold and $1.2 billion for OpFolda. The company also noted pending FDA approval for Voxogo in hypochondroplasia.

View
Proposed Sales
Value
$302.7K
Shares
5.1K
Filed
Nov 18, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 17, 2026
View
Investor Relations
Latest news
BioMarin to Participate in Upcomi…
Published
Nov 4, 2026
View

Performance

5D 20D 120D MTD YTD
BMRN +8.3% +8.5% +11.6% +5.0% +3.4%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY +13.8% +14.8% +17.2% +10.2% -1.6%
Key facts CIK 1048477 CUSIP 09061G101 13F (30d) 576 filings 518 filers Visit website Investor relations